Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report
Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to reshape its workforce and tap local talent pools.
Roche Receives European Commission Approval of Tecentriq® SC With Halozyme’s ENHANZE® Representing The EU’s First Subcutaneous PD-(L)1 Cancer Immunotherapy For Multiple Cancer Types
Reduces treatment time by approximately 80% compared to standard intravenous (IV) infusion
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to IV infusion and is
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries.
Why Is Cancer Focused Poseida Therapeutics Stock Trading Higher Today?
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor
Roche’s Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Roche Holding AG (OTC: RHHBY) has agreed to
Sarepta/Roche’s Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny – Stock Tanks
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk) with Duchenne muscular
Roche Buys Pfizer & Roivant Sciences’ Televant In ~$7.1B Deal
Roche Holding AG (OTC: RHHBY) inked a deal to acquire
Roche Agrees To Acquire Telavant, Including Rights To Novel TL1A-Directed Antibody (RVT-3101), From Roivant Tor $7.1B
Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseases
RVT-3101 is a Phase 3-ready
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
Roche Holdings AG's (OTC: RHHBY) nine months